Practice Guideline: Idiopathic Normal Pressure Hydrocephalus: Response to Shunting and Predictors of Response
Neurol 85:2063-2071, Halperin, J.J.,et al, 2015
Left Atrial Appendage Occlusion vs Standard of Care After Ischemic Stroke Despite Anticoagulation
JAMA Neurol 81:1150-1158, Maarse,M.,et al, 2024
Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020
Efficacy and Tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy
Neurol 91:82-90, Kanner, A.M.,et al, 2018
Efficacy and Tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy
Neurol 91:74-81, Kanner, A.M.,et al, 2018
Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018
Autoimmune Encephalitides: A Broadening Field of Treatable Conditions
Neurologist 22:1-13, Kalman, B., 2017
Cryptogenic Stroke
NEJM 374:2065-2074, Saver, J.L., 2016
Evidence-based Guideline: Treatment of Parenchymal Neurocysticercosis
Neurol 80:1424-1429, Baird, R.,et al, 2013
Patent Foramen Ovale and Cryptogenic Stroke
Stroke 44:2676-2678, Furlan, A.J. and Jauss, M., 2013
Evidence-based Guideline: Antiepileptic Drug Selection for People with HIV/AIDS
Neurol 78:139-145, Birbeck,G.L.,et al, 2012
Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012
Early Surgical Therapy for Drug-Resistant Temporal Lobe Epilepsy
JAMA 307:922-930, Engel, J.,et al, 2012
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:227-276, Furie,K.L.,et al, 2011
Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues
Arch Neurol 68:165-171, Bronstein,J.M.,et al, 2011
Evidence Report: The Efficacy and Safety of Mitoxantrone (Novantrone) in the Treatment of Multiple Sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 74:1463-1470, Marriott,J.J., et al, 2010
Intracerebral Haemorrhage
Lancet 373:1632-1644, Qureshi,A.I.,et al, 2009
Practice Parameter Update: The Care of the Patient with Amyotrophic Lateral Sclerosis: Drug, Nutritional, and Respiratory Therapies (An Evidence-Based Review)
Neurol 73:1218-1226, Miller,R.G.,et al, 2009
Management of Stroke in Infants and Children: A Scientific Statement From a Special Writing Group of the American Heart Association Stroke Council and the Council on Cardiovascular Disease in the Young
Stroke 39:2644-2691, Roach,E.S.,et al., 2008
Second Consensus Statement on the Diagnosis of Multiple System Atrophy
Neurol 71:670-676, Gilman,S.,et al., 2008
Gadolinium-Based MR Contrast Agents and Nephrogenic Systemic Fibrosis
Radiology 242:647-649, Kuo,P.H.,et al, 2007
Position Statement on the Coverage of Anticonvulsant Drugs for the Treatment of Epilepsy
Neurol 68:1249-1250,1245, Liow,K.,et al, 2007
Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack
Stroke 37:577-617, Sacco,R.L.,et al, 2006
Adult Epilepsy
Lancet 367:1087-1100, Duncan,J.S.,et al, 2006
Status Epilepticus: An Evidence Based Guide
BMJ 331:673-677, Walker,M., 2005
Patent Foramen Ovale in Young Adults with Unexplained Stroke
NEJM 353:2361-2372, Kizer,J.R. &Devereux,R.B., 2005
Assessment: Transcranial Doppler Ultrasonography
Neurol 62:1468-1481, Sloan,M.A.,et al, 2004
Efficacy and Tolerability for the New Antiepileptic Drugs I: Treatment of New Onset Epilepsy
Neurol 62:1252-1260, French,J.A.,et al, 2004
Efficacy and Tolerability of the New Antiepleptic Drugs II: Treatment of Refractory Epilepsy
Neurol 62:1261-1273, French,J.A.,et al, 2004
Practice Parameter: Recurrent Stroke with Patent Foramen Ovale and Atrial Septal Aneurysm
Neurol 62:1042-1050, Messe,S.R.,et al, 2004
Practice Parameter:The Care of the Patient with Amyotrophic Lateral Sclerosis (An Evidence-Based Review), Report of the Quality Standards Subcommittee of the AAN
Neurol 52:1311-1323, Miller,R.G.,et al, 1999
Practice Advisory:The Use of Felbamate in the Treatment of Patients with Intractable Epilepsy, Report of the quality Standards Subcommittee of the AAN and the American Epilepsy Society
Neurol 52:1540-1545, French,J.,et al, 1999
Consensus Statement on the Definition of Orthostatic Hypotension, Pure Autonomic Failure, and Multiple System Atrophy
Neurol 46:1470, Schatz,I.J.,et al, 1996
Intravenous Immunoglobulin Treatment of Neurological Disease
JNNP 60:359-361, Otten,A.,et al, 1996
Epilepsy
JNNP 57:264-277, Chadwick,D., 1994